Drizalma Sprinkle is a drug owned by Sun Pharm that first received market authorization on 19 July, 2019. It contains the active ingredient duloxetine hydrochloride and is available in capsule, delayed rel pellets, oral dosage forms.
The generic version of Drizalma Sprinkle may become available after 13 April, 2037, which is the expiry date of the last patent. The release of Drizalma Sprinkle generic is linked to the patents held by Sun Pharm.
Drizalma Sprinkle employs duloxetine hydrochloride, which is effective for the treatment of depression, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.
Drizalma Sprinkle is protected by 4 patents. The most relevant patent for the release of Drizalma Sprinkle generic is patent US11202772 titled 'Duloxetine sprinkles,' which will expire on 13 April, 2037. Below are the details of the patent: